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Abstract The beta-blockers comprise a group of drugs
that are mostly used to treat cardiovascular disorders
such as hypertension, cardiac arrhythmia, or ischemic
heart disease. Each of these drugs possesses at least one
chiral center, and an inherent high degree of enantiose-
lectivity in binding to the β-adrenergic receptor. For
beta-blockers with a single chiral center, the (–) enanti-
omer possesses much greater affinity for binding to the
β-adrenergic receptors than antipode. The enantiomers
of some of these drugs possess other effects, such as
antagonism at alpha-adrenergic receptors or Class III
antiarrhythmic activity. However, these effects gener-
ally display a lower level of stereoselectivity than the
beta-blocking activity. Except for timolol, all of these
drugs used systemically are administered clinically as
the racemate. As a class, the beta blockers are quite
diverse from a pharmacokinetic perspective, as they
display a high range of values in plasma protein bind-
ing, percent of drug eliminated by metabolism or
unchanged in the urine, and in hepatic extraction ratio.
With respect to plasma concentrations attained after
oral or intravenous dosing, in most cases the enanti-
omers of the beta-blockers show only a modest degree
of stereoselectivity. However, the relative magnitude
of the concentrations of the enantiomers in plasma is
not constant in all situations and varies from drug to
drug. Further, various factors related to the drug (e.g.,
dosing rate or enantiomer-enantiomer interaction) or
the patient (e.g., racial background, cardiovascular
function, or the patient metabolic phenotype) may
affect the stereospecific pharmacokinetics and pharma-
codynamics of beta-blockers. An understanding of the
stereospecific pharmacokinetics and pharmacodynam-
ics of beta-blockers may help clinicians to interpret and
predict differences among patients in pharmacologic
responses to these drugs.
INTRODUCTION
In clinical practice, the β-adrenergic antagonists are an
extremely important class of drugs due to their high
prevalence of use. Many have been synthesized and are
commonly used systemically in the treatment of condi-
tions including hypertension, cardiac arrhythmia,
angina pectoris, and acute anxiety, and topically for
open angle glaucoma.  With respect to their clinical
utility, the beta-blockers are normally distinguished
based on their selectivity for beta-receptors. The nonse-
lective beta-blockers, including propranolol, oxpre-
nolol, pindolol, nadolol, timolol and labetalol, each
antagonize both β1- and β2-adrenergic receptors. For
the selective antagonists, including metoprolol,
atenolol, esmolol, and acebutolol, each has much
greater binding affinity for the β1 adrenergic receptor.
The selective beta-blockers are normally indicated for
patients in whom β2-receptor antagonism might be
associated with an increased risk of adverse effects.
Such patients include those with asthma or diabetes, or
patients with peripheral vascular disease or Raynaud's
disease. 
As depicted in Figure 1, a common feature in the
chemical structure of beta-blockers is that there is at
least one aromatic ring structure attached to a side
alkyl chain possessing a secondary hydroxyl and amine
functional group. Each of the available beta-blockers
has one or more chiral centers in its structure, and in
all cases, at least one of the chiral carbon atoms residing
in the alkyl side chain is directly attached to a hydroxyl
group. Except for timolol, which is marketed as S-enan-
tiomer, each of the beta-blockers with one chiral center
(e.g., propranolol, metoprolol, atenolol, esmolol, pin-
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dolol, and acebutolol) is marketed as a racemate con-
sisting of two enantiomers. Additionally, labetalol,
which has two chiral centers (Figure 1), is marketed as
a racemate consisting of four isomers. As for nadolol,
the drug has three chiral centers in its structure (Figure
1). However, the two ring hydroxyl groups (Figure 1)
are in the cis orientation, allowing for only four iso-
mers. 
Figure 1: Chemical structure of major beta-adrenoceptor
blocking agents. The asterisk denotes the chiral carbon.
Amongst chiral drugs, arguably the beta-adrenergic
blocking drugs are one of the best-understood classes
from the perspective of stereoselectivity in pharmacok-
inetics and pharmacodynamics. The enantiomers of β-
blockers possess markedly different pharmacodynam-
ics, and in some cases, pharmacokinetics. Although
there is no defined range of plasma concentrations for
the beta-blockers, for some of them, an effective con-
centration has been proposed (1). The intent of this
review is to summarize what is known of the pharma-
codynamic and pharmacokinetic properties of some of
the major β-adrenergic antagonists in current use. 
STEREOSELECTIVITY IN PHARMACOLOGIC ACTION
The available data regarding the pharmacologic action
of beta-blockers indicate that the interaction of these
agents with beta-adrenoceptors is highly stereoselective
(2-12). Generally, the cardiac beta-blocking activity of
the beta-blockers with two enantiomers resides in their
S (–) enantiomers (2-7), the reported S:R activity ratio
being in the range of 33 to 530 (Table 1). However, the
R (+)-enantiomer has relatively strong activity in
blocking β2 receptors in ciliary process (4) (Table 1).
For sotalol, which has R (–) and S (+) conformation, it
is the R (–) enantiomer that possesses the majority of
the β-blocking activity (8). Both enantiomers of sotalol
share an equivalent degree of Class III antiarrhythmic
potency, however (8).
Carvedilol is a newer agent that is marketed as the race-
mate for the treatment of hypertension and congestive
heart failure (13). This latter indication is unique
amongst the available beta-blockers, for which this
condition is normally a contraindication. Similar to
other beta-blockers, the S (–) enantiomer of carvedilol
is more potent as an antagonist of beta-receptors. Both
the R and S enantiomers, however, are equally effective
in blocking alpha-adrenergic activity (14). This gives
the drug utility in congestive heart failure due to the
combination of decreased vascular resistance (α-adren-
ergic antagonism) and lack of reflex tachycardia (β-
blockade). It should be noted that recent studies (15)
involving low doses of selective β-blockers (e.g., meto-
prolol) display a similar benefit to carvedilol in reduc-
ing mortality in patients with heart failure.
Similar to carvedilol, labetalol (Figure 1), which con-
tains four stereoisomers, is an adrenoceptor blocker
with combined beta- and alpha-receptor blocking prop-
erties (9-11). However, the beta-blocking activity of the
drug is between 3 to 7 folds greater than its alpha-
blocking property (16). Additionally, different isomers
contribute differently to the drug's α and β-blocking
activities (9-11) (Table 1). Whereas the RR isomer is
mostly responsible for the β blocking activity of the
drug, the SR isomer is most potent as a α-adrenoceptor
blocker (9). Both the RS and SS isomers, on the other
hand, show weak antagonistic activities against α and β
receptors (9). Stereoselectivity in blocking beta adreno-
ceptors has also been reported (12) for nadolol (Figure
1), another beta-blocker with four stereoisomers (Table
1). 
STEREOSELECTIVITY IN PHARMACOKINETICS
Absorption 
Generally, beta-blockers are absorbed from the gas-
trointestinal tract via passive diffusion. Therefore, their
absorption is not considered stereoselective. However,
some beta-blockers such as talinolol may undergo an
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intestinal secretion process that may be modestly stere-
oselective, resulting in an apparent nonlinearity in the
kinetics of the drug with increasing oral doses (17).
Nevertheless, despite the suggestion of an active intesti-
nal secretion process, the overall pharmacokinetics of
talinolol are not stereoselective (17).
Distribution
Beta-blockers are basic drugs that bind to both albumin
and α1-acid glycoprotein (AAG) in the plasma.
Because of the asymmetric nature of proteins, binding
of enantiomers to proteins resembles diastereomers.
Therefore, the dissociation rate constant of binding
may be stereoselective. 
The information on the binding of some beta-blockers
to plasma proteins is listed in Table 2.  For acebutolol
(18), pindolol (19), and sotalol (20), which have rela-
tively high free fractions in plasma, the binding
appears to be non-stereoselective (Table 2).
Table 1. Stereoselectivity in the action of Some beta-adrenergic blockers. 
Drug Relative Activity (Ratio) Experimental 
Model 
Biological Response Reference 
– > + Rat Reduction in heart rate and mean arterial 
pressure 
Atenolol 
– > + (46:1) Guinea pig Beta-blocking activity of heart 
– > + (530:1) Beta-blocking activity of heart Betaxolol 
+ > – (190:1) 
Rabbit 
Blocking β2 receptors in ciliary process  

Bucindolol – > +  Dog Myocardial stimulant, vasodilator 
– > + Beta-blocking activity Carvedilol 
– = + 
Rat and 
Rabbit Alpha-blocking activity 

RR > SR; RR > RS; RR > 
SS 
Beta-blocking activity 
SR > RR; SR > RS; SR > 
SS 
Rat 
Alpha-blocking activity 
	
RR-SR > labetalol (2:1) Antagonizing pressor effects of 
phenylephrine and chronotropic effect of 
isoprenaline 
RR-SR > labetalol Alpha1-blocking activity 
Labetalol 
RR-SR > labetalol (3:1) 
Rat 
Beta1-blocking activity 

– > + (33:1) Beta-blocking activity of heart Metoprolol 
+ > – (10:1) 
Rabbit 
Blocking β2 receptors in ciliary process 

Nadolol SQ-12151 > SQ-12150 > 
nadolol > SQ-12148 > SQ-
12149 
Chinese 
hamster ovary 
cells 
Binding values to β1, β2, and β3 cloned 
receptors 

Pindolol – > + (200:1) Guinea pig   Blocking β1 and β2 receptors 

– > + (100:1) Blocking isoprenaline cardiac response Propranolol 
– = + 
Rat 
Frog nerve Local anesthetic effects 

– > + Beta-blocking activity Sotalol 
– = + 
Dog and 
rabbit Class III antiarrhythmic activity 

– > + (44:1) Beta-blocking activity of heart Timolol 
– = + 
Rabbit 
Blocking β2 receptors in ciliary process  


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However, stereoselective binding has been reported
(21-26) for propranolol in both whole plasma as well as
individual serum proteins (Table 2).  As demonstrated
in Table 2, the stereoselectivity in the binding of pro-
pranolol to human serum albumin is opposite of that
observed for the human AAG. Whereas the free frac-
tion of the (+)-enantiomer is higher in AAG, the
opposite is true for albumin (Table 2). The overall ste-
reoselectivity in the binding of propranolol to human
serum, however, resembles that seen with AAG (Table
2).  
A study of the propranolol binding in the maternal
and fetal serum (23) further confirmed the importance
of AAG in the overall extent of binding and stereose-
lectivity of propranolol (Table 2); a significantly lower
concentration of AAG in the fetus blood (14 mg%),
compared with that in the maternal blood (66 mg%),
resulted in much higher free fractions and a change in
the direction of stereoselectivity in binding in the fetal
blood (Table 2). 
Table 2. Protein binding of individual enantiomers of beta blockers.  
Drug Study Matrix Percent 
Unbound 
(–:+) 
Unbound 
Ratio 
(–:+) 
Human plasma (young) 86:84 1.0 Acebutolol 
Human plasma (elderly) 93:93 1.0 
Pindolol  Human plasma 45:45 1.0 
Human plasma 22.0:25.3 0.86 
Human AAG 12.7:16.2 0.79 

Human albumin 64.9:60.7 1.07 
Human plasma 10.9:12.2 0.89 
Human AAG 23.0:30.2 0.76 

Human albumin 51.0:48.2 1.06 
Human plasma (pregnant female) 20.7:22.4 0.92 
Human plasma (fetus)  40.4:38.8 1.04 
Human plasma (young) 11.7:18.0 0.65 
Human plasma (elderly) 12.1:18.6 0.65 
Human plasma (female) 10.9:17.8 0.61 

Human plasma (male) 12.8:18.8 0.68 
Human plasma (male) 9.1:10.8 0.84 
Human plasma (female) 9.2:10.8  0.85 
Propranolol 

 Human plasma 17.6:20.3  0.87 
Human plasma (young) 96:96 1.0 	
Human plasma (elderly) 95:95  1.0 
Sotalol 
 Human plasma (supraventricular tachyarrhythmia 
patients) 
65:62 1.0 
	
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The age and gender of the patients do not appear to
have a substantial effect on the protein binding of pro-
pranolol enantiomers (Table 2). A modestly lower
unbound fraction of (–)-propranolol in females (10.9%,
Table 2) compared with males (12.8%, Table 2)
reported in one study (24) was not observed in a subse-
quent study (25) which reported an unbound fraction
of 9.1 and 9.2 in men and women, respectively (Table
2).
The tissue distribution of the enantiomers of propra-
nolol (27-29) and pindolol (30) have been reported
using laboratory animals.  Collectively, these studies
suggest that while the concentrations of the enanti-
omers of beta-blockers in different tissues may be stere-
oselective, the actual tissue uptake and binding of these
drugs in most cases is non-stereoselective. The apparent
stereoselectivity in the tissue concentrations of these
drugs has been attributed mainly to the stereoselectiv-
ity in the plasma protein binding of the drugs. For
example, Takahashi et al. (28) demonstrated that, com-
pared with the (+)-enantiomer, the (–)-enantiomer of
propranolol reaches higher concentrations in heart,
muscle, gastrointestinal tract, kidney, brain, and lung
of rats. However, this apparent stereoselectivity could
be explained by higher free fraction of (–)-propranolol
in plasma (28).   Similarly, the stereoselective binding
of the propranolol enantiomers to plasma proteins is
the main reason behind an apparent stereoselectivity in
the red blood cell distribution of the drug (31).
It has been shown that both hydrophilic (e.g. atenolol)
and lipophilic (e.g. propranolol) beta-blockers are
stored into and released from the adrenergic nerve end-
ings (32). Further, it has been reported (32, 33) that the
uptake into and release of atenolol from the models of
adrenergic cells are stereoselective, favoring the more
active (–)-enantiomer of atenolol by 2 to 5 fold. Addi-
tionally, a study in humans (34), chronically receiving
racemic atenolol, indicated that the (–)-enantiomer of
atenolol is selectively released into the plasma after
exercise. The exercise-induced stereoselective release of
atenolol from adrenergic nerve ending significantly
changed the (+): (–) plasma concentration ratio of
atenolol from 1.18 (at rest) to 0.64 (after exercise) (34).
The effects of exercise on the stereoselective release of
atenolol are apparently related to the duration of ther-
apy because in disagreement with the above study
using chronic dosing, the exercise-induced release of
atenolol after a single dose of racemic atenolol was not
stereoselective (35).   In contrast to atenolol, the uptake
of propranolol, a more lipophilic beta-blocker, into the
adrenergic nerve cells or models appears to be via pas-
sive diffusion, and, therefore, is not stereoselective (33).
Nonetheless, the stereoselectivity in the storage into
and release of beta-blockers from the adrenergic nerve
endings may have important clinical implications
because it affects the concentration of the active enanti-
omer at its site of action.   
Metabolism
The elimination of most beta-blockers occurs via
hepatic metabolism and/or renal excretion of the
unchanged drug. While the lipophilic beta-blockers,
such as propranolol, are eliminated mostly by metabo-
lism, the more hydrophilic beta-blockers, such as
atenolol and nadolol, are almost exclusively excreted
unchanged in urine. Some aspects of the stereospecific
human metabolism of propranolol and metoprolol,
two widely studied beta-blockers, will be discussed
here.
Figure 2: The schematic presentation of main metabolic
pathways of propranolol in humans. Asterisk indicates the chiral
center. Source: Ref. .
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In man, propranolol is metabolized by three main
pathways of glucuronidation, ring hydroxylation, and
side chain oxidation as depicted in Figure 2 (36). The
ring hydroxylation process may occur at either posi-
tion four or five (Fig. 2), both of them showing sub-
strate stereoselectivity for R (+)-propranolol (36-38).
The hydroxypropranolol is further conjugated with
glucuronic acid, favoring the S (–)-enantiomer, or sul-
fate, favoring the R (+)-propranolol, before excretion
into urine (32).  As for N-dealkylation process (Fig. 2),
the enantioselectivity in the metabolism appears to be
related to the concentration of the drug; whereas at
low substrate concentrations, the R (+)-enantiomer is
preferentially metabolized, the opposite is true at high
propranolol concentrations (36). Based on the urinary
excretion of the propranolol glucuronides in humans,
the formation of propranolol glucuronide, on the other
hand, appears to favor S (–)-propranolol (37). Overall,
the metabolism of propranolol is stereoselective for the
less active R (+) enantiomer, resulting in a higher
plasma concentrations of the S (–)-enantiomer in
humans. 
The metabolism of propranolol is affected by genetic
polymorphism for both CYP1A (mephenytoin hydrox-
ylation) and CYP2D6 (debrisoquine hydroxylation)
isozymes in the liver (39, 40). Based on in vivo studies
(39) in poor and extensive metabolizers of debrisoquine
and mephenytoin and in vitro studies (40) using human
liver microsomes and CYP isoforms, it appears that N-
dealkylation of propranolol is mainly governed by S-
mephenytoin-4-hydroxylase (CYP1A subfamily),
whereas ring hydroxylation is predominantly related
to debrisoquine isozyme (CYP2D6). 
Metoprolol is another beta-blocker that is predomi-
nantly eliminated by hepatic metabolism (41). In
humans, metoprolol is eliminated by several oxidation
pathways, including benzylic hydroxylation (α-
hydroxylation) which results in an active metabolite
and accounts for ∼10% of the dose (42). This pathway
is stereoselective for S (–)-metoprolol. The major meta-
bolic pathway, however, is O-demethylation and fur-
ther oxidation to a carboxylic acid metabolite that
accounts for 65% of the dose (41). O-demethylation
favors R (+)-metoprolol (42) and is responsible for the
stereoselectivity observed in the plasma concentrations
of metoprolol. A third metabolic pathway (N-dealkyla-
tion) accounts for < 10% of the dose in humans (42). 
The oxidation of metoprolol cosegregates with debriso-
quine hydroxylation, and debrisoquine phenotype sig-
nificantly affects the stereoselective metabolism of the
drug (41).  The influence of debrisoquine hydroxyla-
tion phenotype on the pharmacokinetics and pharma-
codynamics of both propranolol and metoprolol is
described later in this review. 
Renal excretion
As mentioned above, renal excretion of the unchanged
drug is the major elimination pathway for hydrophilic
beta-blockers such as atenolol, nadolol, and sotalol. In
contrast to metabolism, the reported stereoselectivity
in the renal clearance of beta-blockers is relatively low,
with (–) :(+) renal clearance ratios being 0.90, 1.1, 1.2,
and 1.05 for metoprolol (43), atenolol (44), pindolol
(19) and sotalol (45), respectively. The small degree of
stereoselectivity reported for the renal clearance of
these drugs is most likely due to an active tubular secre-
tion and/or reabsorption process. A stereoselective
plasma protein binding, as a reason for the observed
stereoselective renal clearance, is unlikely because the
plasma protein bindings of pindolol and sotalol are not
stereoselective (Table 2), and the protein binding of
atenolol and nadolol enantiomers is negligible. Given
the low degree of stereoselectivity in renal clearance,
for those β-blockers subject to a large fraction of dose
excreted in urine, a diminution of renal function might
be expected to cause proportionately equal increases in
plasma concentrations of both enantiomers.
Relative concentrations of enantiomers in plasma
The enantioselectivity in the plasma concentrations of
beta-blockers is a reflection of all the processes (absorp-
tion, distribution, and elimination) involved in the
pharmacokinetics of these drugs. The human kinetic
parameters of various beta-blockers are listed in Tables
3-5. Except for metoprolol (Table 3), carvedilol (Table
3), and propranolol (Tables 4 and 5), the stereoselectiv-
ity in the pharmacokinetics of other studied beta-
blockers is relatively modest (Table 3). For acebutolol,
the active S (–)-enantiomer attains modestly higher
plasma concentrations relative to its antipode (–:+
AUC ratio of 1.2 ± 0.1) (46). This stereoselectivity was
suggested to be due to a stereoselective first pass metab-
olism in favor of the R (+)-enantiomer (46), as reflected
in a slightly higher oral clearance of this enantiomer
(Table 3).
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For atenolol and pindolol, two beta blockers with sub-
stantial elimination through renal excretion, a modest
stereoselectivity in the renal clearance in favor of the
S(–)-enantiomer results in slightly (< 20%) higher
plasma concentrations of the less active R(+)-isomer
(Table 3). Nevertheless, the stereoselectivity in the
plasma concentrations of acebutolol, atenolol, and pin-
dolol are perhaps of minor clinical significance.
After single doses of racemic sotalol to healthy volun-
teers, virtually no stereoselectivity was observed in the
plasma concentrations of the enantiomers (45). The (–)
:(+) ratios of maximum plasma concentration (Cmax)
and area under the plasma concentration-time curve
(AUC) were 1.0 and 0.97, respectively, and the differ-
ences between enantiomers did not attain the level
required for statistical significance (45). There was some
stereoselectivity, however, noted in another study (47)
when repeated doses of sotalol were administered to
patients with supraventricular tachycardia. After at
least 3 days of therapy with 80 or 160 mg of the race-
mate every 12 h, the (–):(+) ratios of steady-state AUC
were 0.87 and 0.91 for the 80 and 160 mg doses, respec-
tively. For both doses, the differences between enanti-
omers were statistically significant. It is not known
why a greater degree of stereoselectivity appears to be
present after repeated dose administration.
The stereoselectivity in the plasma concentrations of
metoprolol is mostly related to the stereoselective
metabolism and first pass effect of the drug. A slight
stereoselectivity in the renal clearance of the drug in
favor of R(+)-metoprolol (Table 3) virtually has no
effect on the plasma stereoselectivity because of the
negligible contribution of this pathway to the overall
elimination of the drug.   Whereas, a preferential
metabolism of (+)-metoprolol in extensive metaboliz-
ers of debrisoquine results in a (–):(+) AUC ratio of
1.37 ± 0.32 (43), the stereoselectivity is reversed [(–)
:(+) AUC ratio of 0.90 ± 0.06] in poor metabolizers of
debrisoquine (Table 3).  
Table 3. Stereospecific pharmacokinetics of some beta blockers in humans after single oral doses of the 
racemates. 
Drug 
(Age in yr, n) 
Dose, 
mg 
Isomer Cmax, 
ng/mL 
Tmax, 
h 
AUC, 
ng·h/mL 
CL,mL/
min/kg 
V, 
L/kg 
CLR, 
mL/min 
t1/2, 
hr 
Ref. 
(–) 246 ± 172 1230 ±375 20 ± 5a 9.2 ± 2.6c 120 ± 38 5.4 ± 1.4 Acebutolol 
(19-40, 12) 
200 
(+) 221 ± 155* 
2.5 ± 0.9 
1030 ± 339* 25 ± 7a,* 11 ± 3.5c,* 124 ± 40 5.7 ± 1.8 


(–) 221 ± 106 1380 ± 380 20 ± 5a 14 ± 8.9c 91 ± 36 7.6 ± 4.0 Acebutolol 
(60-75, 9) 
200 
(+) 209 ± 91 
2.4 ± 1.5 
1180 ± 359 24 ± 7a 14 ±  7.2c 90 ± 36 6.9 ± 3.3 

(–) 226 ± 136 1640 ± 602 1.5 ± 0.4b 0.88 ± 0.34 129 ± 32 6.13d Atenolol 
(23-65, 6) 
50 
(+) 251 ± 138* 
2.7 ± 1.1 
1860 ± 652* 1.4 ± 0.3b 0.79 ± 0.26 120 ± 29* 6.08d 

(–) 34.2 ± 22.5 0.67e 125 ± 66 Carvedilol 
(53 ± 13, 13) 
25 
(+) 73.5 ± 44.3* 1.0e 288 ± 186* 
    

(–)   679 ± 388   70 ± 22 2.9 ± 1 Metoprolol,EM 
(56 ± 1, 6) 
200 
(+)   408 ± 409*   75 ± 22* 2.8 ± 1 
(–)   3430 ± 623   56 ± 25 7.2 ±  1.5 Metoprolol,PM 
(58 ± 11, 6) 
200 
(+)   3800 ± 635*   62 ± 26* 7.7 ± 1.7* 

(–) 33 ± 7 1.7 ± 0.4 209 ± 73   222 ± 66 2.62d Pindolol 
(19-36, 8) 
15 
(+) 36 ± 10 1.6 ± 0.5 244 ± 90*   170 ± 55* 2.85d 


(–) 619 ± 164 6760 ± 1200 158 ± 38 7.9 ± 1.2 Sotalol 160 
(+) 615 ± 167 
3.1 ± 0.6 
6950 ± 850 
  
150 ± 25 8.2 ± 0.7 

a Oral clearance or clearance/F  
b Systemic clearance 
c V/F 
d Harmonic half life 
e Median 
* Significantly different from the (–)-enantiomer. 
Abbreviations: Cmax =  maximum plasma concentration; Tmax = time to reach Cmax; AUC = area under the plasma concentration-time curve; CL= clearance; V=  
volume of distribution; CLR= renal clearance; t1/2 = plasma half life; EM, extensive metabolizers of debrisoquine; PM, poor metabolizers of debrisoquine; F = oral 
bioavailability. 
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For propranolol, a higher free fraction of the R (+)-
enantiomer in blood (Table 2) results in a higher vol-
ume of distribution for this enantiomer after the IV
administration of the racemate (Table 4). Additionally,
the systemic clearance of R (+)-propranolol is slightly,
but significantly, higher than that of S (–)-propranolol
(Table 4), resulting in a slightly higher plasma concen-
tration of S (–)-propranolol after the IV administration
of the drug.
However, oral administration magnifies this stereose-
lectivity (Table 5), presumably due to a stereoselective
first pass metabolism in favor of R (+)-propranolol
(48). After the oral administration of the racemate, the
(–) :(+) AUC ratios for propranolol ranged from 1.0 to
1.6 in various studies (Table 5).   The possible reasons
for this wide range of ratios are explained in the follow-
ing section.
FACTORS AFFECTING THE PHARMACOKINETICS AND 
PHARMACODYNAMICS OF BETA BLOCKERS
Various factors related to the drug and the patient may
affect the stereospecific pharmacokinetics and pharma-
codynamics of beta-blockers. Factors related to the
drug include the dosing rate of the drug and the inter-
actions between the enantiomers themselves and
between the enantiomers and other drugs.  Factors
related to the patient may be the age and gender, racial
background, disease states, and the patient metabolic
phenotype. 
Input rate
Theoretically (49, 50), the oral rate of input of racemic
drugs with stereoselective metabolism may affect the
plasma concentration ratio of the enantiomers. This is
because the rate of input of the drug into the portal
vein may have a different effect on the degree of satura-
tion of the metabolic pathways of the enantiomers,
with resultant stereoselectivity in the first pass metabo-
lism of these drugs. Indeed, as early as 1982, Silber et al.
(51) reported that the (–):(+) steady state plasma con-
centration ratios of propranolol significantly decreased
with an increase in the daily dose of the drug; the ratios
(mean ± SD) were 2.45 ± 1.12, 1.78 ± 0.60, and 1.51 ±
0.05 after the oral multiple doses of 160, 240, and 320
mg/day, respectively.  The same trend is observed
when results of several studies are combined in Figure
3.  The input rate-dependent change in the ratio may
be attributed to a dose-dependent saturation of the first
pass metabolism of propranolol with a greater satura-
tion for the R (+)-enantiomer. 
Table 4. Stereospecific pharmacokinetics (mean ± SD) of propranolol in humans after intravenous doses of 
the racemate 
Dose Subjects Isomer CL, 
L/min 
V, L t1/2, hr Reference 
(–) 1.03 
± 0.27 
286 
± 52a,b 
3.5 
± 0.5 
0.1 mg/kg 4 M, 1 F 
21-38 yr 
(+) 1.21 
± 0.34* 
337 
± 53a,b,* 
3.6 
± 0.6 


(–) 0.77 
± 0.14 
273 ± 32c 4.1 
± 0.5 
12 M, 
White 
(+) 0.84 
± 0.16 
303 ± 45c 4.2 
± 0.3 
(–) 0.95 
± 0.27** 
329 
± 98** 
4.2 
± 0.8 
232 ± 28 µCi along with 16th dose of 80 mg 
t.i.d. po 
13 M, 
Black 
(+) 1.1 ± 0.3** 397 
± 119** 
4.3 
± 0.9 

aVolume of distribution of the beta phase. 
bBased on a 70-kg subject. 
cSteady-state volume of distribution. 
*Significantly different from the value for the (–)-enantiomer. 
**Significantly different from the value for the same isomer in the white group. 
Abbreviations: CL= systemic clearance; V=  volume of distribution; t1/2 = plasma half life. 

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Table 5. Stereospecific pharmacokinetics (mean ± SD) of propranolol in humans after single or multiple oral 
doses of the racemate (±) or pure enantiomers (– or +) 
Drug, Dose 
(mg) 
Subjects Isomer Cmax, 
ng/mL 
AUC, 
ng·h/mL 
CLO, 
L/min 
t1/2, hr Reference 
(–) 81.7 ± 31 329 ± 118 2.3 ± 0.7 4.5 ± 1.2 (±), 80, single 
(+) 46.5 ± 25* 217 ± 114* 4.0 ± 2.0a,* 5.2 ± 2.4 
(–), 40, single 
5 M, 3 F, 24-27 
yr 
(–) 74.6 ± 16 274 ± 83** 2.7 
± 0.7a,** 
4.4 ± 1.0 

(–) 27 ± 18 119 ± 80 2.8  (±), 40, t.i.d. 
(+) 20 ± 15* 84 ± 67* 4.0  
(–), 20, t.i.d. 
10 M, 24 ± 1 yr 
(–) 25 ± 14 98 ± 45 3.4  

(–) 84.7 ± 37 523 ± 333 1.6 ± 0.8a 3.6 ± 0.9 9 M, 28 ± 9, 
White (+) 61.9 ± 33 391 ± 296 2.5 ± 1.8a 3.6 ± 1 
(–) 49.8 ± 
23*** 
351 ± 156*** 2.6 
± 1.5a,*** 
4.0 ± 0.8 
(±), 80, single 
10 M, 27 ± 8, 
Chinese 
(+) 34.8 
± 26*** 
232 ± 111*** 4.2 
± 2.5a,*** 
3.9 ± 0.8 


(–)   2.1 ± 0.5 4.1 ± 0.5 12 M, White 
(+)   2.9 ± 0.9 4.2 ± 0.3 
(–)   3.3 ± 1.7*** 4.2 ± 0.8 
(±), 80, t.i.d. 
13 M, Black 
(+)   5.0 ± 4.2*** 4.3 ± 0.9 

(–)  387 ± 194 1.7 5.5 ± 2.4 6 M, 6 F, 25-33 
yr (+)  329 ± 177* 2.0 4.3 ± 1.7 
(–)  475 ± 204 1.4 11.4 ± 
5.9**** 
(±), 80, t.i.d. 
6 M, 6 F, 62-79 
yr 
(+)  375 ± 187* 1.8 11.1 
± 4.8**** 

(–) 30 ± 11 152 ± 33 4.56 ± 0.9 3.6 ± 0.7 6 M, 24-32 yr 
(+) 18 ± 6 100 ± 20 6.93± 1.5 4.3 ± 1.2 
(–) 42 ± 19**** 266 ± 
118**** 
2.76 ± 
1.2**** 
4.8 ± 0.5 
(±), 80, single 
6 M, 65-80 yr 
(+) 27 ± 12**** 171 ± 74**** 4.55 ± 
1.7**** 
4.8 ± 0.5 


(–) 290 ± 183 1600 ± 1040 1.5 ± 1.9a 3.3 ± 1.3 (±), 160, 
b.i.d. (+) 275 ± 183 1560 ± 1020 1.5 ± 1.8a 3.6 ± 1.2 
(–), 80, b.i.d. (–) 267 ± 190 1590 ± 1410 1.3 ± 0.9a 3.0 ± 1.3 
(+), 80, b.i.d. 
15 M, 20-35 yr 
(+) 212 ± 140 1120 ± 807 1.9 ± 1.8a 3.0 ± 1.2 

aBased on a 70-kg subject. 
*Significantly different from the value for the (–)-enantiomer. 
**Significantly different from the value for the (–)-enantiomer after the administration of the racemate. 
***Significantly different from the value for the same enantiomer in the white group. 
****Significantly different from the value for the same enantiomer in the young group. 
Abbreviations: Cmax =  maximum plasma concentration; AUC = area under the plasma concentration-time curve; CLO= oral 
clearance (clearance/F); t1/2 = plasma half life; F = oral bioavailability 
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In contrast to Silber et al. (51), Bleske et al. (52) could
not detect any significant effect of input rate on the ste-
reoselectivity in the propranolol pharmacokinetics.
The lack of effect of input rate in the latter study is
perhaps because only single and relatively low doses of
the drug were used (52). Simulations (49, 50) have
shown that the effects of input rate on the stereoselec-
tive pharmacokinetics are significant in the non-linear
input ranges when the input rate approaches the maxi-
mum velocity of the metabolism. Additional pharma-
cokinetic/dynamic studies are needed to determine the
clinical significance of the effects of input rate on the
stereoselective metabolism of propranolol.
Figure 3: The average steady state (–):(+) AUC ratio of
propranolol as a function of daily dose of the racemic drug in
different studies. Keys: ●,  Ref. ; ▲, Ref. ; ■, Ref. ;
❑, Ref. 	; ❍, Ref. 	
Interactions
The two enantiomers of a racemic drug may interact
with each other at different pharmacokinetic or phar-
macodynamic levels. This type of interaction has been
studied for atenolol (3) and propranolol (53-55). For
atenolol, there was no pharmacokinetic or pharmaco-
dynamic interaction between the two enantiomers; the
half-dosed S (–)-atenolol produced the same effect as
did the racemic atenolol (3). Additionally, the plasma
concentration-time profiles of S (–)-atenolol were iden-
tical after the administration of the racemate or the
half-dosed pure enantiomer. On the other hand, both
single (53) and multiple (54) dose studies have shown
that there is a significant interaction between the enan-
tiomers of propranolol. When administered as pure
enantiomer, as opposed to the racemate, R (+)-propra-
nolol tends to show lower plasma concentrations (54).
However, the kinetics of the more active S (–)-enanti-
omer appear to be the same whether it is administered
as a pure enantiomer or racemate (53-55).
In addition to enantiomer-enantiomer interactions, a
racemic drug may interact with other drugs stereoselec-
tively. For instance, stereoselective interactions have
been reported in man between propranolol and calcium
channel blockers (56, 57), cimetidine (58), and quinidine
(36).  Calcium channel blockers nicardipine (56), dilt-
iazem (57), and verapamil (57) all decreased the first-
pass metabolism of both enantiomers of propranolol.
However, this inhibitory effect was stereoselective for
the R (+)-enantiomer in the case of both verapamil (57)
and nicardipine (56), resulting in a significant increase
in the (+) :(–) AUC ratios in plasma.  In terms of
effects, nicardipine did not increase the blood pressure
reduction effect of propranolol (56), a phenomenon
that may be explained by a more significant pharmaco-
kinetic effect on the less active R (+) enantiomer. Simi-
larly, cimetidine decreased the oral clearance of R (+)-
propranolol to a more significant degree than that of
the S (–)-enantiomer (58). As for quinidine, human liver
microsome studies (36) indicated that this selective
inhibitor of CYPD26 reduced the ring hydroxylation of
propranolol in a stereoselective manner in favor of R
(+)-propranolol. This was in agreement with in vivo
studies (59) showing 180% and 100% increases in the
plasma AUCs of R (+) - and S (–)-propranolol, respec-
tively, because of quinidine co-administration. Interest-
ingly, all these studies have shown that the inhibition of
the metabolism of propranolol by different drugs is ste-
reoselective for R (+)-propranolol.
In addition to the inhibition of the metabolism of pro-
pranolol, verapamil reportedly (60) inhibits the metab-
olism of metoprolol, another extensively metabolized
beta-blocker. As mentioned in the metabolism section,
the O-demethylation pathway is the main metabolic
pathway for the metabolism of metoprolol accounting
for 65% of the dose. Verapamil significantly inhibits
this pathway in a stereoselective manner favoring inhi-
bition of the metabolism of R (+)-metoprolol (60). The
interaction of verapamil and metoprolol results in clin-
ically significant adverse reactions, presumably due to
higher plasma concentrations of metoprolol. 
Cimetidine not only reduces the metabolism of beta-
blockers such as propranolol, it is also known to act as
an inhibitor of tubular secretion of a number of
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organic cations. Therefore, it is not surprising to see
that the renal clearance of pindolol is substantially and
stereoselectively reduced by co-administration of this
drug (61).  The administration of 400 mg cimetidine
twice a day for 2 days before and 2 days after pindolol
administration resulted in 26% and 34% reductions in
the renal clearances of S(–)- and R(+)-pindolol, respec-
tively.  Therefore, the plasma concentrations of the R
(+)-enantiomer increased more drastically (47%) than
those of the S (–)-enantiomer (38%) in the presence of
cimetidine (61). Because renal clearance accounts for
only 50% of pindolol elimination, the significant
increases in the plasma concentrations of pindolol
enantiomers because of cimetidine co-administration
cannot be explained based on the inhibition of its renal
clearance only. Apparently, cimetidine also reduces the
metabolism of pindolol. 
Age and gender
The effect of age on the stereospecific pharmacokinet-
ics of propranolol has been the subject of several stud-
ies (24, 62-64) with conflicting results. For instance,
while Colangelo et al. (64) and Lalonde et al. (62)
reported no significant changes in the oral clearances of
the propranolol enantiomers with advancing age, oth-
ers (24, 63) have reported a significant decline in the
clearance of both enantiomers in the elderly.  Addition-
ally, in contrast to Zhou et al. (63) who showed no sig-
nificant differences in the plasma half lives of the
propranolol enantiomers between the young and the
elderly, Gilmore et al. (24) reported that the half lives
of both propranolol enantiomers in the elderly were
more than two-fold longer than those in the young.
These conflicting results are mostly due to different
designs of these studies with regard to the dose, dura-
tion of therapy (single versus multiple dosing), dura-
tion of sampling, and the number of subjects used.
Overall, these studies suggest that the clearance of both
enantiomers of propranolol is reduced in the elderly.
Additionally, in the presence of extended duration of
sampling (e.g. =24 hr), the terminal half lives of the
propranolol enantiomers are apparently longer in the
elderly than in the young.  However, the reduction in
the oral clearance and prolongation of plasma half-life
appear to be to the same extent for both enantiomers.
These data indicate that the known decreased response
to beta-blockers in the elderly subjects cannot be
explained by stereoselective pharmacokinetic differ-
ences between the young and elderly.
For acebutolol, an advance in the age resulted in a de-
crease in creatinine clearance and an associated decrease
in the renal clearance of both enantiomers of the parent
drug and its metabolite diacetolol (18). However, the
decrease in the renal clearance of the enantiomers was
not stereoselective. On the other hand, a reduction in
creatinine clearance with advancing age was associated
with a significant decrease in the (–):(+) AUC ratio of
the drug (from 1.3 to 1.1 when creatinine clearance
declined from 90 to 45 mL/min), suggesting that aging
has a stereoselective effect on the other pathways (e.g.
metabolism) of acebutolol elimination.
In terms of gender, non-stereoselective studies (65)
have clearly shown that the oral clearance, and not the
systemic clearance, of propranolol is significantly
(63%) higher in men than in women. This difference
was attributed to significant increases in the side-chain
oxidation and glucuronidation of propranolol during
the first pass metabolism in men (65). Available stereo-
selective studies (24, 25), however, have failed to show
a significant difference between males and females in
the main pharmacokinetic parameters of propra-
nolol.   Again, this discrepancy may be related to meth-
odological differences and the power of statistical tests
used in these studies. Future, well-designed studies are
needed to test the effects of gender on the stereospecific
pharmacokinetics of propranolol.
The importance of delineation of the stereospecific
pharmacokinetics in explaining gender-related pharma-
codynamics was demonstrated recently for labetalol
(66).  Labetalol dose was titrated to a specific antihyper-
tensive effect in 14 men and 5 women with ages rang-
ing from 40 to 63 and 40 to 56 years, respectively. The
dose-corrected AUC values for total labetalol in
women were 80% higher than those in men. However,
the antihypertensive effects were the same for both
groups. This discrepancy could be easily explained by
stereoselective differences in the pharmacokinetics of
labetalol isomers in men and women; whereas the con-
centrations of the alpha blocking isomer (SR) and two
relatively inactive isomers of labetalol (SS and RS) were
between 60 to 80% higher in women, the plasma con-
centrations of the main beta-blocking isomer (RR)
were the same in both groups, resulting in similar anti-
hypertensive effects in men and women. 
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Genetic factors
Ethnic background: It is known that Chinese subjects
are more responsive than white subjects to the same
dose or plasma concentrations of racemic propranolol.
A study (67) investigated whether this could be attrib-
uted to higher (–) :(+) AUC ratios in Chinese subject,
compared with the ratio in white population.
Although the plasma concentrations of both enanti-
omers were substantially lower in Chinese volunteers,
the ratio was the same in both populations (67), sug-
gesting a pharmacodynamic difference in these two
populations with regard to the beta-blockade effect. 
In contrast to the Chinese, the black population
responds less to the same dose of propranolol, when
compared with the white population. Sowinski et al.
(48) showed that both the systemic and oral clearances
of both enantiomers of propranolol are substantially
higher in blacks than whites. This difference was
mostly attributed to a higher intrinsic clearance of pro-
pranolol enantiomers, in association with a slightly
lower (9%) hepatic blood flow in blacks.   The limited
available information on the effects of ethnicity on the
pharmacokinetics of propranolol suggests that the
racial differences in the effects of this drug cannot be
attributed to the stereoselectivity in the pharmacoki-
netics of the drug. Rather, these differences may be due
to pharmacodynamic differences among ethnic popula-
tions.
Metabolic phenotype of the patient: As mentioned in
the Metabolism section, the metabolic phenotype of
patients may significantly affect the metabolism and,
consequently, the overall pharmacokinetics and phar-
macodynamics of propranolol and metoprolol.  For
propranolol, Ward et al. (39) reported that although
the ring hydroxylation and N-dealkylation processes
were deficient in poor metabolizers of debrisoquine
and mephenytoin, respectively, the overall oral clear-
ance of the propranolol enantiomers were modestly
reduced in volunteers with one of these deficiencies
(Table 6). Additionally, the stereoselectivity in the
plasma concentrations in these volunteers were not dif-
ferent than that in extensive metabolizers (Table 6).
However, a combined poor metabolism of mepheny-
toin and debrisoquine (observed only in one volunteer)
substantially reduced the oral clearance of both enanti-
omers and abolished the stereoselectivity in the plasma
concentration of propranolol (Table 6). It should be
noted that the cosegregation of both deficiencies is
expected to be very low (0.4% of the population) (39).
For metoprolol, Lennard et al. (41) demonstrated that
after a 200-mg oral dose, the plasma concentrations of
racemic metoprolol in poor metabolizers of debriso-
quine were 6 times higher than those in the extensive
metabolizers. Additionally, when the beta blockade
effect was plotted against the plasma concentrations of
the racemic drug, the relationship was shifted to the
right in poor metabolizers (43). This discrepancy was
attributed to the differences in the stereoselectivity in
the metabolism and plasma concentrations of the drug
in the two groups. Whereas the (–) :(+) metoprolol
AUC ratio was 1.37 ± 0.32 (mean ± SD) in the exten-
sive metabolizers, the ratio was 0.90 ± 0.06 in poor
metabolizers (43). Therefore, the same concentrations
of the racemate would contain less of the active (–)-
enantiomer in poor metabolizers, shifting the effect-
concentration relationship to the right.
Table 6. Oral clearance and plasma half lives of propranolol enantiomers after oral administration of the 
racemate (80 mg) to volunteers with different phenotypes of debrisoquine and mephenytoin hydroxylation.a 
Oral Clearance, ml/min Group n 
(+)-Propranolol (–)-Propranolol (+):(–) Ratio 
EM 6 2670 ± 697 1910 ± 632 1.42 ± 0.53 
PMD 4 1860 ± 1110 1420 ± 788 1.25 ± 0.06 
PMM 5 2010 ± 909 1401 ± 595 1.42 ± 0.09 
PMD/M 1 918 850 1.08 
aSource: Reference . 
Abbreviations: EM, extensive metabolizers of debrisoquine and mephenytoin; PMD, poor metabolizers of debrisoquine and 
extensive metabolizers of mephenytoin; PMM, poor metabolizers of mephenytoin and extensive metabolizers of debrisoquine; 
PMD/M, poor metabolizers of both debrisoquine and mephenytoin. 

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Although the metabolism of both propranolol and
metoprolol are affected by debrisoquine phenotype,
the above data clearly shows that the effect is more sub-
stantial for metoprolol. Debrisoquine polymorphism
also significantly affects the kinetics of another beta-
blocker, bufuralol (68). In contrast to metoprolol, how-
ever, poor metabolism of debrisoquine intensified the
stereoselectivity in the plasma concentrations of
bufuralol [(–):(+) plasma concentration ratio of 1.8
and 2.6 at 3 hr in extensive and poor metabolizers,
respectively] (68).  This was due to a significant reduc-
tion of the metabolism of (–)-bufuralol by ring hydrox-
ylation in poor metabolizers of debrisoquine (68).
Therefore, the effect of debrisoquine hydroxylation
phenotype on the degree and direction of stereoselec-
tivity in pharmacokinetics varies with each beta-
blocker.
Congestive heart failure
For highly metabolized drugs, altered cardiac output
may influence the drug plasma concentrations in the
presence of moderate to high hepatic extraction ratio,
conditions that are true for carvedilol enantiomers (69).
Tenero et al. (13) demonstrated that in patients with
Class III or IV congestive heart failure, the plasma con-
centrations of carvedilol enantiomers were substan-
tially higher than those in healthy volunteers.
Additionally, patients with Class IV congestive heart
failure had consistently higher plasma concentrations
(up to two-fold) than those patients with Class III con-
gestive heart failure (13). Similar to healthy volunteers,
patients with congestive heart failure exhibited stereo-
selectivity in both Cmax and AUC of the drug (13).
However, the R:S AUC ratios observed in these
patients (~1.9) were lower than those observed in oth-
erwise healthy young (2.8) and elderly (2.3) volunteers
(13), suggesting that the effects of congestive heart fail-
ure on the pharmacokinetics of carvedilol are stereose-
lective.
Although it was not mentioned by the authors, there
does appear to be a difference in the level of stereoselec-
tivity in AUC between the patients with Class III and
Class IV congestive heart failure (13). The reported
mean R(+):mean S(–) AUC in the Class IV patients
were consistently higher (20-43%) than the correspond-
ing ratios in the patients with Class III congestive heart
failure across a dosage range of 6.25-50 mg adminis-
tered every 12 hr. The ratios of mean R(+):mean S(-)
Cmax were also consistently higher in the Class IV
patients (14-18%).  Overall, these data suggest that
Class IV congestive heart failure patients attain higher
plasma concentrations of both enantiomers, in favor of
the R-enantiomer, when compared with Class III
patients.     
CONCLUSION
For the most part, the enantiomers of the β-adrenergic
antagonists share similarities with respect to pharmaco-
logic effects, with the (–)-enantiomer usually possessing
a substantially higher ability to bind to β-adrenergic
receptors. In some cases, such as sotalol, carvedilol, and
labetalol, the enantiomers may possess other qualities
that add to the beta-blocking properties of the drug.
As for pharmacokinetics, there does not seem to be a
general pattern in the degree and/or direction of stere-
oselectivity among different beta-blockers.  This is per-
haps because β-adrenergic antagonists encompass a
wide spectrum of pharmacokinetic properties, with
low to high degrees of plasma protein binding, extent
of excretion into urine as unchanged drug, and hepatic
extraction ratios. Additionally, the degree and direc-
tion of stereoselectivity in the pharmacokinetics of
these drugs are susceptible to change because of patient
and/or disease characteristics.  Because of the signifi-
cant enantioselectivity in the pharmacologic effects of
beta-blockers, a stereoselective change in the pharma-
cokinetics of these drugs may be associated with an
altered pharmacodynamic profile. An understanding of
the stereospecific pharmacokinetics and pharmacody-
namics of beta-blockers may help clinicians to interpret
and predict differences among patients in pharmaco-
logic response to these drugs. 
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